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Centre Médical de l’Institut Pasteur, Institut Pasteur, Paris, France
☯ These authors contributed equally to this work.
¶ Membership of the LeishMan Network and the French Cutaneous Leishmaniasis Study group is provided in
the Acknowledgements section
* romain.guery@groupeconfluent.fr (RG); johannes.blum@swisstph.ch (JB); pierre.buffet@inserm.fr (PB)
Abstract
Background
Cutaneous leishmaniasis (CL) is frequent in travellers and can involve oro-nasal mucosae.
Clinical presentation impacts therapeutic management.
Methodology
Demographic and clinical data from 459 travellers infected in 47 different countries were col-
lected by members of the European LeishMan consortium. The infecting Leishmania spe-
cies was identified in 198 patients.
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Principal findings
Compared to Old World CL, New World CL was more frequently ulcerative (75% vs 47%),
larger (3 vs 2cm), less frequently facial (17% vs 38%) and less frequently associated with
mucosal involvement (2.7% vs 5.3%). Patients with mucosal lesions were older (58 vs 30
years) and more frequently immunocompromised (37% vs 3.5%) compared to patients with
only skin lesions. Young adults infected in Latin America with L. braziliensis or L. guyanensis
complex typically had an ulcer of the lower limbs with mucosal involvement in 5.8% of
cases. Typically, infections with L. major and L. tropica acquired in Africa or the Middle East
were not associated with mucosal lesions, while infections with L. infantum, acquired in
Southern Europe resulted in slowly evolving facial lesions with mucosal involvement in 22%
of cases. Local or systemic treatments were used in patients with different clinical presenta-
tions but resulted in similarly high cure rates (89% vs 86%).
Conclusion/Significance
CL acquired in L. infantum-endemic European and Mediterranean areas displays unex-
pected high rates of mucosal involvement comparable to those of CL acquired in Latin
America, especially in immunocompromised patients. When used as per recommendations,
local therapy is associated with high cure rates.
Author summary
Cutaneous and muco-cutaneous leishmaniasis (CL and MCL) are disfiguring diseases
caused by a worldwide distributed parasite called Leishmania and its 20 species. Clinical
manifestations span a wide continuum from single nodular lesion to disseminated form
with mucosal involvement.
No randomized clinical trial has ever been done exclusively in travellers and medical
management is poorly evidence-based or based very predominantly on data obtained in
endemic countries. Articles and reviews almost invariably propose a dichotomic view,
with Old World CL described as a benign disease in contrast to New World CL strongly
associated with destructive mucosal lesions.
Our study is the first prospective clinical study providing a detailed description of the
clinical presentation and risk of mucosal involvement in CL in several hundreds of
patients, with frequent formal identification of the infecting Leishmania species. The har-
monized data collection in patients infected in many transmission foci worldwide enabled
direct comparisons of clinical patterns induced by different Leishmania species, and on
the outcome following treatment with either local or systemic regimens. The study is
based on an international harmonized data collection that allowed a wide capture of para-
sitologically confirmed cases. In striking contrast with previous assumptions, the study
shows that CL acquired in Europe displays unexpected high rates of mucosal involvement
comparable to those of CL acquired in Latin America, especially in immunocompromised
travellers. It also shows that when used as per recommendations, local therapy is associ-
ated with high cure rates.
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Introduction
Ninety-eight countries and 3 territories are considered endemic for leishmaniasis, a vector-
born parasitic disease caused by a protozoan from the Leishmania genus [1]. While visceral
leishmaniasis is a severe disease, cutaneous leishmaniasis (CL), that affects the skin and can
involve the mucosa of nose and mouth, is not life-threatening. It causes however disfiguring
lesions, scarring and stigma [2]. CL affects 0.7 to 1 million individuals each year and its global
burden is increasing [3,4].
According to existing surveillance networks, CL is not infrequent in travellers visiting
endemic areas [5]. The absence of mandatory notification in most countries and the self-cur-
ing course of a proportion of lesions hamper robust estimation of the burden of CL in travel-
lers. Recent conflicts in the Middle East have been linked to a rise in the incidence of CL in
migrants and refugees [6].
Textbook and reference reviews have long proposed a dichotomic view, with Old World CL
often described as a benign cutaneous disease in contrast to New World CL strongly associated
with destructive mucosal lesions. Thus, assessment of the mucosal involvement in travellers is
discussed only for New World CL and almost never for Old World CL in clinical practice. To
provide a detailed description of the clinical presentation and risk of mucosal involvement of
CL, both directly impacting treatment decisions, we analysed its presentation in travellers
from data deposited in a large international database. The harmonized data collection by clini-
cians attending patients infected in many transmission foci worldwide enables direct compari-
sons of clinical patterns induced by different Leishmania species, and the outcome following
treatment with either local or systemic regimens.
Methods
Ethics statement
This observational study (DR-2013-041; N˚912650) was approved by the French National
Agency regulating data protection (Commission Nationale de l’Informatique et des Libertés).
Patients (or their legal representative) provided verbal or written consent according to national
regulations for use of anonymized data on clinical findings, treatment received, clinical out-
come and laboratory results. No genetic analyses of human DNA were performed.
Data collection
From 2006 through 2012 data collection was initiated by a French referral network as reported
elsewhere [7,8]. A standardized case report form was used for baseline demographical, clinical
and biological data and a second case report form was used to collect outcomes, identification
of Leishmania species and adverse events, at least 42 days after the expert had provided treat-
ment advice to the attending physician. From 2012 through 2019, the analysis was extended to
several European countries by teams belonging to the LeishMan network.[9] LeishMan is a
multicentre international medical project aiming to improve the management of leishmaniasis
through harmonization of medical practices and collection of data in a common system. The
variables of the LeishMan database were translated from those of the initial French database.
Currently, the consortium gathers 50 experts affiliated to 30 institutions in 11 European coun-
tries (Belgium, France, Germany, Italy, Norway, Portugal, Spain, Sweden, Switzerland, the
United Kingdom, The Netherlands). Data were pseudonymously and prospectively collected
by experts from each institution. The database is hosted by Epiconcept since 2012 and has
been certified as “Health Data Host” (ISO standards ISO 27001 and elements of ISO 2000–1
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and ISO 27018). Demographic, clinical and biological data were filled in an electronic case
report form.
Definitions
A patient was considered to have cutaneous/mucocutaneous leishmaniasis if she/he had: (1)
cutaneous and/or mucosal lesions; (2) laboratory confirmation of the presence of Leishmania
as follows: presence of amastigotes in smears or tissue sections and/or promastigotes in culture
and/or positive molecular testing by Polymerase Chain Reaction (PCR) on a skin sample.
Mucosal leishmaniasis (ML) refers to the presence of mucosal lesion(s) without skin
involvement. Muco-cutaneous leishmaniasis (MCL) refers to the simultaneous presence of
both mucosal and skin lesions. Mucosal involvement refers to both ML and MCL. Post-Kala
Azar Disease (PKDL) was defined as new skin lesions in a patient who had recovered from vis-
ceral leishmaniasis. Disseminated cutaneous leishmaniasis was defined as CL with more than
10 lesions in 2 non-contiguous anatomical sites. Immunocompromised patients include
patients with at least one of the following treatments or conditions: immunosuppressive ther-
apy (e.g>5mg/day equivalent prednisone during more than 3 months, chemotherapy, metho-
trexate, monoclonal antibodies or small molecules targeting immune cells or their products
[e.g. anti-TNF agents], HIV infection, primary immunodeficiencies). HIV testing was not sys-
tematically done and/or collected as variable.
Healing in CL was defined as complete re-epithelialization for an ulcer or disappearance of
induration for a papular lesion at least 42 days after treatment start [10]. Treatment regimen
and dosage mostly followed national or international guidelines [11–13].
Information regarding the infecting Leishmania species was captured in the case report
form by the expert based on the molecular identification performed by local laboratories in
each centre or by national reference laboratories. Clustering of (sub)species in complexes fol-
lowed a recent classification of Leishmania species [14]. Briefly, L. infantum was included in
the L. donovani Complex, L. major was included in the L. major Complex. L. braziliensis and
L. peruviana were included in the L. braziliensis Complex, and L. panamensis and L. guyanensis
were merged into L. guyanensis Complex.
Patients eligible for local therapy based on clinical parameters
We determined the proportion of patients with CL potentially eligible for a local therapy (eg,
paromomycin cream or intralesional antimony + cryotherapy). Criteria for eligibility were as
per the LeishMan consensus for Treatment of Cutaneous and Mucosal Leishmaniasis in Trav-
ellers and WHO recommendations [12,15]. Criteria were: localized CL,� 4 lesions,� 4cm in
largest induration diameter, no immunosuppression, lesion type (papulo-nodular or dry crust
or wet crust), lesion site compatible with treatment method (eyelid and peribuccal lesions
excluded).
Statistics
Continuous variables are presented as median [interquartile range] and categorical variables
as numbers (frequencies). Categorical variables were compared using chi-square test or Fish-
er’s exact test as appropriate. Continuous variables were compared using Student’s t-test or
Wilcoxon-Mann-Whitney test as appropriate. A two-tailed p-value < .05 was considered sta-
tistically significant. Statistical analyses were performed using R software 3.1 version (R Devel-
opment Core Team, 2008) using GMRC Shiny Stat application developed by CHU de
Strasbourg (2017).
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Results
Geography
A total of 459 patients with CL were recruited into the study cohort between 2006 and 2019,
corresponding to 464 infections, i.e., 5 patients had a second episode (Fig 1). Patients were
included by 10 centres from 7 countries in Europe (Tables A and B in S1 Table). There were
279 cases (60%) and 185 cases (40%) acquired in Old World and New World, respectively. The
infection had been acquired in 47 different countries (Fig 2). Top 3 countries of acquisition
were French Guiana (n = 41), Peru (n = 37) and Costa Rica (n = 28) for the New World and
Spain (n = 48), Syria (n = 36) and Morocco (n = 34) for the Old World (Tables C and D in S1
Table). Countries of acquisition could not be determined in 10 cases (2%) because patients
had travelled to multiple endemic countries in a short period of time.
Demography
The median age of patients in the study cohort was 30 years; 99 infections (21%) occurred in
children <16 years. There were marked differences in age distributions between travellers Vis-
iting Friends or Relatives and tourists (S1 Fig). The main reasons for travel in children were
Visiting Friends or Relatives (57%) or migration (25%) while travelling reasons in adults were
more heterogeneous and influenced by travel-destination. For example, tourists returning
from the New World (often referred to as “backpackers”) were younger than tourists from the
Old World (median age 30 years vs 48 years; p = 0.03). Migration-related infections were only
observed in the Old World while military personal or expatriates acquired the infection almost
exclusively in the New World. Patients were immunocompromised in 5% of cases, and a previ-
ous history of leishmaniasis was reported by 8% of patients in the cohort. Compared to those
infected in the Old World, patients infected in the New World were more frequently males
(75% versus 54.5%), and more rarely immunocompromised (0.6% versus 8%) (Table 1).
Fig 1. Flow chart of entries in the LeishMan database and selected analyses. Infection, Relapse or Reinfection
correspond to a documented episode of visceral or cutaneous leishmaniasis, with or without mucosal involvement. �
patients with multiple follow-up visits or samples. Notes: A “Patient” file corresponds to demographic information. A
“Sample” file corresponds to one sample collected in one site with one technique at one date (eg. PCR on skin biopsy of
right hand collected the 25th of May 2017). Abbreviations: CL, cutaneous leishmaniasis; VL, visceral leishmaniasis
https://doi.org/10.1371/journal.pntd.0009863.g001
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Clinical features of Cutaneous Disease
Most patients had lesions limited to the skin (n = 440; 95%), with typically one or two ulcerated
lesions of the limbs that had been present for 3 months prior to diagnosis and were 10 to 30
mm-wide (Table E in S1 Table). Compared to lesions acquired in the Old World, lesions
acquired in the New World were more frequently ulcerative (75% versus 47%), larger (median
diameter 30 mm versus 20 mm), more frequently localized on the limbs (61% versus 47%) and
more frequently associated with nodular lymphangitis (30% versus 6%) (Table 1).
Identification of the infecting Leishmania complex in 198 patients (Table F in S1 Table)
showed species-associated demographic and clinical patterns. For patients with no species
identification, diagnosis was mostly confirmed by histology or smear, i.e., samples on which
identification cannot be performed. Excluding rare species and incomplete species (Table F in
S1 Table), we focused on the 5 most frequent infecting complex species (affecting a sub-cohort
of 166 patients (Fig 1). This analysis showed that typically, children infected with L. major in
Africa had rapidly evolving multiple lesions of the limbs; children and young adults infected
with L. tropica had a lesion of the face without mucosal involvement; 40–70 year-old tourists
infected with L. infantum in Southern Europe had a slowly evolving papulo-nodular lesion in
the face and mucosal involvement in 22% of cases; young adults infected in Latin America
with L. braziliensis or L. guyanensis had a rapidly evolving ulcer of the lower limbs with lym-
phangitis and mucosal involvement in 35% and 6% of cases, respectively (Fig 3 and Table 2).
Immunosuppression was reported in 22 patients and was related to ongoing therapy with anti-
cancer chemotherapy (n = 1), ustekinumab (n = 1), methotrexate (N = 5), TNFα antagonists
(n = 5), prolonged corticosteroids with or without other immunosuppressive drugs (azathio-
prine (n = 1), mycophenolate mofetil (n = 1) or corticosteroids alone (n = 4)), or HIV infection
(n = 3), or Good syndrome (n = 1).
Mucosal involvement
Mucosal involvement was observed in 20 patients (4.3%), 15 were infected in the Old World
and 5 in the New World (Table 3). In the 5 patients from the New World 2 had ML and 3 had
MCL, while in the 15 patients from the Old World 7 had ML and 8 had MCL. The risk of
Fig 2. Number of cases reported from each country of acquisition (464 infections in 459 patients). Created with
mapchart.net.
https://doi.org/10.1371/journal.pntd.0009863.g002
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Table 1. Comparative features of cutaneous leishmaniasis by continent(s) of acquisition.
New World Old World p-value
185 infections 279 infections
Age, median [IQR] 30 [24–38] 32 [10–58] 0�81
Male 75% (138) 54% (152) <0�01
Immunocompromised 0�6% (1/177) 8% (21/264) <0�01
Type of traveller NA
Tourist 61% (109/180) 36% (96/269)
Visiting Friends and Relatives 7% (12/180) 43% (117/269)
Migrant 0% (0/180) 14% (39/269)
Expatriate (worker,
missionary)
12% (21/180) 3% (8/269)
Soldier 13% (24/180) 0% (0/269)
Others 8% (14/180) 3% (9/269)
Type of cutaneous leishmaniasis NA
Localized Cutaneous 96% (178) 94% (262)
Muco-cutaneous 2% (3) 2�5% (7)
Mucosal 1% (2) 2�5% (7)
PKDL 0�5% (1) 0�3% (1)
Disseminated cutaneous
leishmaniasis
0�5% (1) 0�3% (1)
Muco-cutaneous and visceral
leishmaniasis
0% (0) 0�3% (1)
Delay from first symptoms to
the first consultation (in
months), median [IQR]
3 [2–4] 4 [3–7] <0�01
Number of lesions, median
[IQR]
1 [1–2�2] 2 [1–4] <0�01
Type of lesions < 0.01
Ulcer (wet crust) 75�5% (139/184) 47�5% (128/271)
Papulo-nodular 5�5% (10/184) 25�5% (69/271)
Dry crust 14% (26/184) 16% (44/271)
Squamous plaque 3% (5/184) 8�5% (23/271)
Others 2% (4/184) 1% (3/271)
Scar or new papule on a
previous scar
0% (0/184) 1�5% (4/271)
Lesion localization <0.01
Upper limb 32% (58/183) 31% (84/274)
Face, neck and scalp 17% (31/183) 38% (104/274)
Lower limb 29% (53/183) 16% (45/274)
Hand 8% (15/183) 8% (21/274)
Trunk 7% (13/183) 2% (6/274)
Feet 4% (7/183) 4% (10/274)
Neck and Scalp 3% (6/183) 1% (4/274)
Diameter of largest lesion
(millimeter), median [IQR]
30 [20–43�5] 20 [10–35] <0�01
Nodular lymphangitis� 30% (56) 6% (16) <0�01
Notes.
�Nodular lymphangitis was defined as subcutaneous nodules in proximity to the primary lesion and/or dilated
palpable lymphatic vessels in the form of a “beaded cord,” and/or regional lymphadenitis
Univariate analysis. Categorical variables not included in the univariate analysis (indicated p-value as “NA”). Data
are % (n) unless indicated.
Abbreviations: IQR, interquartile range; PKDL, Post Kala-azar Dermal Leishmaniasis.
https://doi.org/10.1371/journal.pntd.0009863.t001
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having mucosal involvement at presentation was 5.3% in patients with lesions acquired in the
Old World and 2.7% in patients infected in the New World. Countries of acquisition of New
World mucosal or muco-cutaneous leishmaniasis were Bolivia (2 cases), Costa Rica (1 case),
French Guiana (1 case), Nicaragua (1 case). For Old World leishmaniasis with mucosal
involvement, countries of acquisition were Spain (7 cases), France (2 cases), Italy (2 cases),
Greece (2 cases), Oman (1 case), Turkey (1 case). We observed 10 MCL, 9 ML, and one MCL
with visceral involvement and inaugural skin lesions in a patient with AIDS (CD4 count 67/
mm3). Mouth and laryngeal lesions were observed in 6/13 cases from Old World (missing
data in 2 patients) and 1/5 case from New World, while lesions of nasal cavity were observed
in 7/13 cases from Old World and 5/5 cases from New World. Seven of 15 infections (47%)
with mucosal involvement in the Old World were observed in immunocompromised patients
while no patient was immunocompromised in the New World subgroup with mucosal
involvement. A previous history of leishmaniasis was reported in 5 of 20 patients with mucosal
involvement. CL, ML or VL had been diagnosed in 1, 2 and 2 patients respectively. In all
patients except one (a previous VL episode 20 years before), the mucosal involvement occurred
less than 5 years (median = 4 years) after the first episode. Analysis in the subgroup of patients
with an identified Leishmania species found a prevalence of mucosal involvement of 22%,
5.8%, 0% and 0% for L. (infantum)/donovani Complex, L. braziliensis/L. guyanensis Complex,
L. tropica Complex and L. major respectively (Fig 3 and Table 2).
Local or systemic therapy
More than 10 different treatment regimens were used by physicians in the network (Table 4).
Compared to patients who received systemic therapy, patients treated with local therapy were
more frequently infected in the Old World (88% vs 40%, p< 0.0001), had smaller lesions
(median 19mm vs 31 mm, p< 0.0001), less frequently associated with nodular lymphangitis
Fig 3. Comparative features of 166 cases of cutaneous leishmaniasis by main infecting species. Abbreviations: IQR, interquartile
range; VFR, visiting friends and relatives.
https://doi.org/10.1371/journal.pntd.0009863.g003
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7.5% vs 28.3%, p< 0.0001), and similar number of lesions (median 2 vs 1.5, p = 0.51)
(Table 4). These different approaches applied in these different patient populations resulted in
similar cure rates (89% vs 86%) at first evaluation with a median full duration of follow-up of
80 days [IQR 59–111]. As previously observed “No specific treatment”, which corresponds to
washing lesions with soap and water followed by semi-occlusive dressing, was associated with
high (81%) cure rate [7]. Patients treated with this approach were mainly infected in OW
(90%; 19/21). Due to small numbers within each subgroup, analysis of treatment outcome
has not been made in respect to infecting species within the groups Old World CL and New
world CL.











Age, median [IQR] 27 [23–33] 32 [27–37] 18.5 [6–46] 26 [12–50] 56 [47–66]
Male 76% (26) 61% (11) 54% (28) 50% (13) 50% (18)
Immunocompromised 0% (0) 0% (0) 6% (3) 0% (0) 18% (6)
Type of traveller
Tourist 73% (24) 50% (9) 24% (12) 8% (2) 70% (25)
Visiting Friends & Relatives 3% (1) 17% (3) 69% (35) 44% (11) 25% (9)
Migrants, Expatriate, Soldiers and
Others
24 % (8) 33% (6) 7.8 % (4) 48% (12) 5.5 % (2)
First 3 countries of acquisition
Peru (12) Costa Rica (8) Tunisia (10) Syria (10) Spain (11)
Bolivia (9) French Guiana (7) Algeria (10) Tunisia (4) France (4)
French Guiana (5) Brazil, Suriname, Peru (1+1
+1)
Senegal (8) Morocco (3) Italy + Malta (4)
Delay from first symptoms to the first
consultation, median [IQR]
2 [1,5-3] 3 [2-3] 3 [2-3] 6 [5-12] 7 [3-12]
Number of lesions, median [IQR] 1 [1-2] 2 [1-3] 4 [2-8] 1 [1-2] 1 [1-2]
Type of lesions
Ulcer (wet crust) 85% (28) 88% (16) 63% (32) 35% (9) 47% (15)
Papulo-nodular 0% (0) 6% (1) 23% (12) 31% (8) 25% (8)
Dry crust 9% (3) 6% (1) 12% (6) 11% (3) 19% (6)
Squamous plaque 0% (0) 0% (0) 2% (1) 19% (5) 9% (3)
Others 6% (2) 0% (0) 0% (0) 4% (1) 0% (0)
Lesion localization
Upper limb 18% (6) 28% (5) 44% (23) 34% (9) 24% (8)
Face, neck and scalp 15% (5) 16% (3) 19% (10) 46% (12) 40% (13)
Lower limb 43% (14) 28% (5) 29% (15) 8% (2) 18% (6)
Hand 6% (2) 22% (4) 6% (3) 12% (3) 12% (4)
Trunk 6% (2) 6% (1) 0% (0) 0% (0) 6% (2)
Feet 12% (4) 0% (0) 2% (1) 0% (0) 0% (0)
Diameter of largest lesion (mm) , median
[IQR]
30 [20-39] 40 [25-50] 30 [15-43] 20 [10-30] 7 [3-12]
Nodular lymphangitis 35% (12) 44% (9) 12% (6) 12% (3) 6% (2)





0% (0) 0% (0) 22% (8)
ML(4)
MCL(4)
Note. Data are % (n) unless indicated. Abbreviations: IQR, interquartile range
https://doi.org/10.1371/journal.pntd.0009863.t002
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Table 3. Comparative features in patients with or without mucosal involvement at presentation.
No mucosal involvement With mucosal involvement
444 infections 20 infections p value
Age, median [IQR] 30 [18–51] 58 [33–65] <0�001
Age > 50 years 27% (119) 65% (13) <0�001
Male 62% (274) 80% (16) 0�160
Immunocompromised 3% (15) 37% (7) <0�001
Region of acquisition 0�250
Old World 59�5% (264) 75% (15)
New World 40�5% (180) 25% (5)
Delay from first symptoms to the first consultation, median [IQR] 3 [2–6] 5 [3–12] 0�057
Number of lesions, median [IQR] 2 [1–3] 1.5 [1–3] 0�287
Face, neck or scalp involvement (excluding pure mucosal forms) 29% (123/428) 64% (7/11) 0.020
Large lesion� 50% (196) 64% (7) 0.560
Nodular lymphangitis 15�5% (69) 15% (3) 1
Data are % (n) unless indicated.
�: > 4 cm2 (corresponding to a diameter of 23mm)
Abbreviations: IQR, interquartile range.
https://doi.org/10.1371/journal.pntd.0009863.t003
Table 4. Clinical characteristics of patients and healing rates according to treatment administration modality (systemic versus local).
Local treatment Systemic treatment
n = 107 n = 113 p value
Patients infected in Old World 94 (88) 45 (40) <0,0001
Age, median [IQR] 30 [15–57] 30 [21–51] 0�71
Number of lesions, median [IQR] 2 [1–4] 1�5 [1–3] 0�51
Diameter of largest lesion (mm), median [IQR] 19 [10–30] 31 [20–50] <0�0001
Delay from first symptoms to the first consultation,
median [IQR]
4 [3–6] 3 [2–4] 0�008
Nodular lymphangitis 8 (4,5) 32 (28,5) <0�0001
Immunosuppression or diabete mellitus 12 (11) 5 (4,5) 0�05





No specific treatment � 17/21 (81) Antimonial therapy (MA or SSG) 30/34 (88)
Intralesional MA or SSG +/-
Cryotherapy ��
70/75 (93) Amphotericin B (liposomal or
deoxycholate���)
7/12 (58)
Topical Paromomycin 7/9 (78) Fluconazole 11/12 (92)
Others: surgery (n = 1),
imiquimod (n = 1)
1/2 (50) Miltefosine 38/43 (88)
Pentamidine Isethionate 10/11 (91)
Other: SSG + pentoxifylline (n = 1) 1/1 (100)
Data are n (%) unless indicated. Healing rate = first evaluation after at least 42 days of treatment initiation (median follow-up of 80 days [IQR 59–111]).
Note
�Wash lesion and wound dressing
��two patients received cryotherapy alone
��� all patients except one received liposomal Amphotericin B
Abbreviations: MA, meglumine antimoniate; SSG, sodium stibogluconate
https://doi.org/10.1371/journal.pntd.0009863.t004
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Patients treated with non-systemic therapy
In patients with CL acquired in the New World, healing after day 42 occurred in 12 of 13
(92%) managed with local therapy, and in 55 of 68 (81%) managed with systemic therapy
(p = 0.32). In patients with Old World CL, healing after day 42 occurred in 83 of 94 (88%)
managed with local therapy and in 42 of 45 (93%) managed with systemic therapy.
Patients with CL eligible for local therapy
Among 348/440 patients with localized CL and all available clinical criteria (see Methods), we
found that at least 208/348 patients (60%) were eligible for local therapy. Among them, 90 and
118 patients had been infected in the New World and Old World respectively.
Discussion
Cutaneous Leishmaniasis (CL) displays a diversity of lesion aspect, number, size, and location
on the body surface, including the potential extension to mucosae of the nose, mouth, pharynx
and larynx. These features determine the selection of the most appropriate treatment regi-
mens, from simple wound dressing to long courses of potentially toxic parenteral drugs. In
this cohort of 459 European patients with CL infected in 47 countries from 4 continents, we
show that mucosal involvement (that includes both purely mucosal or mixed cutaneous and
mucosal infections) was present in less than 5% of patients and was similarly infrequent in sub-
jects infected either in Latin America (“New World”, 2.7%) or in Europe, Africa or Asia (“Old
World”, 5.3%). Forms caused by the 5 most frequent infecting complex species (L. major, L.
tropica, L. infantum, L. braziliensis, and L. guyanensis), identified in 166 patients, were each
associated with distinct features. In particular, no mucosal involvement was observed in
patients infected with either L. major or L. tropica, whereas it affected 6% of patients infected
with L. braziliensis or L. guyanensis complex (2 MCL, 1 ML) and 22% of patients infected with
L. infantum (4 ML, 4 MCL), in whom this complication was strongly (though not exclusively)
related to pre-existing immunosuppression. This new set of data on lesions characteristics and
on the risk of mucosal involvement will form a solid basis to refine treatment recommenda-
tions, based on an optimized benefit-to-risk analysis.
We observed 4 typical patterns of CL presentation. Young adults infected in the New
World with L. braziliensis or L. guyanensis complex typically had a single, large ulcerative
lesion on the lower limb. L. major- and L. tropica-infected subjects were predominantly chil-
dren and young adults, who typically had either multiple lesions located on the upper limbs or
a single lesion on the face. L. infantum-infected subjects were predominantly older than 40
years, and typically had a single small lesion in the face. Interestingly, travelers returning from
South and Central America are predominantly young backpackers visiting deep forests. In
terms of age and lesion characteristics, this population resembles that of young infected native
patients living in areas where leishmaniasis is endemic. Taken together, these clinical patterns
should help attending physicians recognize typical forms of CL, hopefully reducing the diag-
nostic delay that currently averages 3 months. Discriminating the respective contributions of
parasite-, vector- and host-related factors in these new phenotypes is beyond the scope of our
current approach but the sustained, multisite, multiparametric surveys performed by the
LeishMan network and other groups worldwide will provide information to more precisely
revisit the pathogenesis of human leishmaniasis [9].
It was surprising that infections acquired in the Old World (and more specifically in Europe
or some Mediterranean countries) had higher rates of mucosal involvement than infections
with L. braziliensis or L. guyanensis complex acquired in Latin America. The prevalence of
mucosal involvement at baseline was 4.3% in the cohort which is consistent with the rate
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(usually <7%) observed in studies including travellers [5,16]. In our study, the unexpected,
low rate of mucosal involvement in infections acquired in the New World contrasts with the
unexpected, relatively high rate in infections acquired in the Old World. High rates of mucosal
involvement patients with Old World leishmaniasis, especially in L. infantum infection, has
been recently observed in some but not all studies in travellers [17–19]. The increasing number
of immunocompromised patients, probably more keen to travel to European countries than to
Latin America, likely contributes to the rising incidence of this complication [20]. A previous
study from France also suggested a risk of visceral dissemination that we did not observe in
our large cohort [21]. Immunosuppression seems to play an important role in the pathogenesis
of ML in the Old World, while its role in ML in New World is more difficult to determine, as
many apparently immunocompetent patients do develop ML.
Systemic treatment is warranted in patients with L. infantum mucosal infection, in whom
miltefosine and liposomal amphotericin B seem effective [8,22]. Therefore, in immunosup-
pressed patients with cutaneous lesions due to L. infantum, miltefosine and liposomal ampho-
tericin B should probably be used, in the hope of preventing the subsequent occurrence of
mucosal involvement that is frequently multifocal with this species (Fig 3). Of interest how-
ever, we confirm here recent observations showing that liposomal amphotericin B is not highly
effective in CL caused by Leishmania species other than L. infantum [8,23].
In the subpopulation of patients in whom it was used, local therapy was effective. Compared
to patients who received systemic therapy, patients treated with local therapy were more fre-
quently infected in the Old World, had smaller lesions, and less frequent nodular lymphangitis.
Arguably, these differences reflect predominantly treatment choices by physicians, based on
the continent of infection and, to a lesser extent, on the applicability of local treatment. Local
and systemic therapy were thus used in different patient populations but resulted in similarly
high cure rates (89% vs 86%). This tells little on the intrinsic power of these different
approaches but suggests that local treatment was appropriate in most patients in whom it was
used, i.e., that criteria defined in the LeishMan consensus were accurate [11,12,16]. Local ther-
apy is now proposed by national and international recommendations not only for Old World
but also for a proportion of patients with New World CL [24]. In the small number of patients
with New World CL treated locally, healing was almost the rule in this cohort, suggesting that
more patients may benefit from this approach in the future. These results match those of pro-
spective studies in endemic countries but larger prospective studies are needed before a robust
conclusion can be reached in the specific context of CL in travellers [16,25–27]. Not all patients
may be eligible to local therapy. In particular, whether infection acquired in Bolivia is compati-
ble with local therapy is still a matter of controversy. A higher risk of mucosal involvement in
travellers returning from Andean countries especially Bolivia has indeed been reported [16].
Solomon and colleagues found that 17 of 145 (11.7%) Israeli travellers with CL acquired in
Amazon Basin in Bolivia received a diagnosis of ML [28]. We observed a prevalence of 9.5%
(2/21) of mucosal involvement in travellers from Bolivia in our study, which matches the
5–15% rate indicated in a quasi-exhaustive review of the literature and the 11.5% rate reported
in a recent large cohort of travellers by Boggild and al. [5,16]. Detecting subsequent mucosal
relapse through an extended follow-up was beyond the immediate scope of our study. How-
ever, as most teams involved in the LeishMan consortium are reference centres for leishmania-
sis in their respective country, they are expected to attend most patients with secondary
mucosal involvement, and capture corresponding information in the common database. The
similar risks of mucosal involvement across these different reports suggest that very few if any
cases of were missed by our consortium during the study period. In our cohort, a previous epi-
sode of leishmaniasis was reported in 20% of patients with mucosal involvement. Several
teams in our consortium give to CL patients a note mentioning the diagnosis of leishmaniasis
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and the significant (though relatively low) risk of oro-nasal complications that may occur
years to decades after the initial episode. Our results suggest that a similar information should
also be provided after a VL episode.
Approximately two thirds of patients of our cohort were eligible for local therapy when fol-
lowing guidelines in travellers based on lesions number, size, location and preexisting condi-
tions [7,12,15]. Even though there may have been some heterogeneity in therapeutic
management during the study period, the general algorithm we described in 2013 has
remained our consortium’s therapeutic management backbone. Cryotherapy followed by
intralesional injections of pentavalent antimony is difficult to perform on several skin locations
(lips, eyelids, genitalia, hands and feet), and in remote endemic areas where liquid nitrogen is
not available and where injections are potentially harmful. In young patients with many and/
or large lesions this effective yet painful approach is vastly suboptimal [11]. By contrast, appli-
cation of paromomycin-based ointments is limited only by the site of application (ie. peribuc-
cal and eyelids), and is well accepted by children and patients with many lesions. It has proved
effective in several randomized trials in the Old and New World [25,26,29,30]. Gaps and issues
in its development have been thwarted by some teams who developed local yet effective paro-
momycin formulations, including in Bolivia (Guéry & Buffet, personal data) [27].
This study has limitations. The number of mucosal or mucocutaneous episodes was too
small to enable a robust multivariate analysis of the risk factors for mucosal involvement.
Because this is a common surveillance program and not a prospective, comparative clinical
trial, we could not capture follow-up data in all patients, hence the need for a careful interpre-
tation of our observations regarding therapy. Not least, HIV testing was not systematically
done which may limit our conclusions regarding the impact of immunosuppression on the
clinical spectrum of cutaneous leishmaniasis. Nevertheless, this robust description of clinical,
parasitological and therapeutic features of cutaneous leishmaniasis in almost half a thousand
of travelers, reveals a moving landscape, where the risk of mucosal involvement is not limited
to travels in the New World and effective treatments of CL are not limited to systemic therapy.
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30. Salah AB, Buffet PA, Morizot G, Massoud NB, Zâatour A, Alaya NB, et al. WR279,396, a Third Genera-
tion Aminoglycoside Ointment for the Treatment of Leishmania major Cutaneous Leishmaniasis: A
Phase 2, Randomized, Double Blind, Placebo Controlled Study. PLOS Neglected Tropical Diseases.
2009; 3: e432. https://doi.org/10.1371/journal.pntd.0000432 PMID: 19415122
PLOS NEGLECTED TROPICAL DISEASES Clinical diversity and treatment results in Tegumentary Leishmaniasis
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009863 October 13, 2021 18 / 18
